- Home
- TRP vs REGN Comparison
TRP vs REGN Comparison
Compare TRP & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRP | REGN |
|---|---|---|
| Founded | 1951 | 1988 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6B | 68.8B |
| IPO Year | 2003 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TRP | REGN |
|---|---|---|
| Price | $63.37 | $809.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 25 |
| Target Price | $79.67 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 1.6M | 762.0K |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.88% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 18.95 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $7.51 | $12.45 |
| Revenue Next Year | $2.45 | $10.13 |
| P/E Ratio | ★ $25.89 | $42.40 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $49.27 | $541.00 |
| 52 Week High | $71.47 | $821.11 |
Technical Indicators
Market Signals| Indicator | TRP | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 78.34 |
| Support Level | $62.27 | $738.17 |
| Resistance Level | $64.95 | $818.06 |
| Average True Range (ATR) | 1.61 | 21.82 |
| MACD | -0.24 | 4.11 |
| Stochastic Oscillator | 12.65 | 94.89 |
Price Performance
Historical ComparisonAbout TRP TC Energy Corporation
TC Energy operates natural gas transmission assets across North America. Segments are determined by country of operation, but both Canadian and US operations are interconnected. Mexican operations are disconnected from the US and only have one customer, the state utility CFE. They also operate power generation assets, with the largest being the Bruce Power nuclear plant.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.